Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 495 (1 June 2009) | doi:10.1038/nbt0609-495
TNF-blocker triple approval
Abstract
A new tumor necrosis factor alpha (TNF-α) blocker with a unique once-monthly dosing schedule has been approved, but despite its advantages, few believe it will shake up the market. Simponi (golimumab) won approval from the US Food and Drug Administration for three rheumatology indications—rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis—in April, and from Health Canada earlier that month.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
